

CASE REPORT

Open Access

Efficacy of aerobic physical retraining in a case of combined pulmonary fibrosis and emphysema syndrome: a case report

Giuseppe De Simone², Giovanna Aquino¹, Claudio Di Gioia², Gennaro Mazzarella³, Andrea Bianco^{1*} and Giuseppe Calcagno¹

Abstract

Introduction: Combined pulmonary fibrosis and emphysema has recently been recognized as a syndrome but remains under-diagnosed. Neither clinical management nor therapeutic approaches have been clearly defined. Pulmonary rehabilitation has not been considered within the therapeutic options for combined pulmonary fibrosis and emphysema. In this case we explored the potential benefits of a specific aerobic physical retraining program in the management of combined pulmonary fibrosis and emphysema.

Case presentation: We describe the case of a 65-year-old Caucasian man with combined pulmonary fibrosis and emphysema and respiratory failure who was receiving long-term oxygen therapy. Our patient underwent physical retraining with moderate intensity aerobic and breathing exercises for four weeks. Clinical and motor tests, as well as questionnaires assessing quality of life and depression levels, were performed prior to and following the retraining. At the end of the retraining program a relevant reduction of long-term oxygen therapy requirement was registered; improvements in terms of physical performance, quality of life, and mood were observed in our patient but no change in respiratory parameters.

Conclusions: A program of aerobic physical retraining appears to be beneficial to patients with combined pulmonary fibrosis and emphysema and may be considered as an additional therapeutic option.

Keywords: Aerobic physical retraining, Combined pulmonary fibrosis and emphysema, CPFE, Pulmonary rehabilitation

Introduction

High-resolution computed tomography (HRCT) scanning has enhanced recognition of the simultaneous occurrence of emphysema and pulmonary fibrosis and, recently, combined pulmonary fibrosis and emphysema (CPFE) has been defined as a syndrome. This syndrome is characterized by upper lobe emphysema and lower lobe fibrosis [1]. Common risk factors resulting in epithelial lung alterations may contribute to emphysema and pulmonary fibrosis despite clinical, radiological, and pathologic differences [2-4]. Coexistence of emphysema and fibrosis are more likely to occur in smoking-induced

parenchymal pulmonary damage [5,6]. CPFE is still under-diagnosed and clinical management as well as therapeutic approaches have not yet been clearly defined. In this case we explore the potential benefits of a specific aerobic physical retraining program, which has not yet been considered within the therapeutic options for CPFE.

Case presentation

We report the case of a 65-year-old Caucasian man who had previously smoked cigarettes (40 pack-years) who had CPFE with several comorbidities, including hypertension, type II diabetes, and depression. Before his CPFE diagnosis our patient had been affected by chronic bronchitis for 12 years. His diagnosis of CPFE was confirmed by thoracic HRCT showing areas of intralobular

* Correspondence: andrea.bianco@unimol.it

¹Department of Medicine and Health Sciences, "V Tiberio" University of Molise, Campobasso, Italy

Full list of author information is available at the end of the article

interstitial and septal thickening with peripheral bilateral distribution in addition to centrilobular emphysema of both his upper lobes. On admission to our rehabilitation clinic, our patient exhibited chronic respiratory failure, reporting dyspnea on exertion and productive cough; our patient was receiving long-term oxygen therapy (LTOT) with 2.5L/min of flow during 24 hours as his peripheral capillary oxygen saturation (SpO_2) steeply declined when oxygen therapy was discontinued ($SpO_2=84\%$). Spirometry showed a relatively mild restriction although his diffusion lung capacity for carbon monoxide (DLCO) was 44% of predicted. Concurrent pulmonary hypertension (PAP 60mmHg) was diagnosed by color doppler echocardiography.

Our patient's pharmacological therapy consisted of high dose inhaled steroids, acetyl-cysteine 1200mg once daily, angiotensin-converting-enzyme inhibitor (Lisinopril) 10mg once daily, and aspirin 100mg once daily. Respiratory and physical exercise test assessments were carried out at admission and discharge; in addition, quality of life (St. George Respiratory) and depression level (Geriatric Depression Scale) questionnaires were administered by a clinical psychologist. Our patient performed the six-minute walk test (6MWT) to evaluate his aerobic physical performance according to the European Respiratory Society/American Thoracic Society recommendation, 2014. The test was performed by an exercise physiologist indoors, along a long, flat, straight, enclosed corridor with a hard surface of 30 meters, and results reported as distance (meters) covered in six minutes. His usual medical regimen was continued and oxygen therapy during the test was administered via a portable oxygen tank. As required by standard protocol, our patient decided the speed of the walk, stopping as required and resuming the test when recovered. Before, during, and after the test, his heart rate and oxygen saturation were reordered using a professional oximeter, and dyspnea levels and overall fatigue were assessed according to the Borg Scale and Visual Analogue Scale (VAS) before and immediately after exercise test. After two weeks in our rehabilitation unit, our patient was clinically stabilized and enrolled in the retraining program for four weeks. The retraining program took place in the cardiorespiratory gymnasium of our rehabilitation unit. Written consent was obtained from our patient before starting the exercise program.

Each retraining session was supervised by an exercise physiologist monitoring heart and respiratory rate, oxygen saturation, blood pressure, and level of dyspnea. Our patient underwent the exercise program for two sessions per day up to 30 minutes each, five days per week, for a four-week period. The training included one session of aerobic exercise and one session of breathing technique. For aerobic training, he exercised on a

treadmill, with a speed of 2.5km per hour and 0% of slope. The intensity of aerobic exercise was adapted to our patient's functional capacity on the basis of his 6MWT results, in accordance with aerobic exercise intensity recommended by American Thoracic Society Guidelines 2006 for pulmonary rehabilitation. Therefore, the work rate of training corresponded to 50% to 60% of his maximum heart rate and the training began at a work rate equal to 50%. When our patient reached the level of exercise at 10 minutes without intolerable dyspnea (Borg rating of breathlessness of <5), the workload (speed and/or elevation) and duration of exercise were increased by 10% [7]. Progressive exercise training was employed for his respiratory muscles; the training consisted of diaphragmatic breathing and inspiratory muscle training, through an inspiratory threshold, at 40% to 50% of his initial maximal inspiratory pressure (PiMax). During training our patient received oxygen therapy to maintain $SpO_2 >92\%$; a flow reduction of 15% was made each week.

After the four-week retraining program, because his arterial blood gas analysis showed a PaO_2 increase of 11% and PCO_2 decrease of 5.6% on oxygen with a flow of 2.5L/min, it was possible to reduce his LTOT to a flow of 1.5L/min for 24 hours to compensate hypoxemia. The oxygen requirement reduction observed may have been due to the strengthening of his respiratory muscles, which allowed improvement of his exercise capacity [8]. His pulmonary artery systolic pressure, estimated by transthoracic two-dimensional echocardiography, improved by 16% in terms of cardiac index and pulmonary vascular resistance [9]; no significant lung function changes were observed. Relevant improvements in exercise capacity, dyspnea rating, health-related quality of life, and levels of depression were also demonstrated after the pulmonary rehabilitation program. His 6MWT showed an increase of distance walked by 133%. His dyspnea scores were reduced: the level of dyspnea at rest (the Modified Medical Research Council Dyspnea Scale) decreased from 3.0 to 2.0, Borg Scale during exercise was reduced from 9.0 to 5.0, and his post-exercise VAS decreased from 8.0 to 5.0; there was only a minor increase in PiMax of 17%. Our patient's adherence to the retraining program was good and no adverse events occurred. Table 1 reports the test results collected before and after the retraining program.

Discussion

In this case study we evaluated whether a patient with CPFE, a disease which has not yet been considered for pulmonary rehabilitation, can benefit from an aerobic retraining program. Emphysema and pulmonary fibrosis are progressive lung diseases that may be associated with comorbidities and systemic consequences [10-14]. CPFE

Table 1 Results of cardiorespiratory and clinical tests before and after a retraining program in a patient with combined pulmonary fibrosis and emphysema

Test	Assessment before retraining program	Assessment after retraining program		
Respiratory functional tests	FEV1/FVC	78%	FEV1/FVC	77%
• Spirometry	FEV1	79% of predicted value	FEV1	82% of predicted value
	FVC	73% of predicted value	FVC	75% of predicted value
• Diffusion lung capacity for carbon monoxide	DLCO	44% of predicted value	DLCO	47% of predicted value
	PaO ₂	63.4mmHg	PaO ₂	70.4mmHg
Arterial blood gas analysis on oxygen 2.5L/min	PaCO ₂	35.6mmHg	PaCO ₂	33.6mmHg
	pH	7.46	pH	7.369
Dyspnea scales				
• Modified Medical Research Council		3.0		2.0
• Visual Analogue Scale		8.0		5.0
• Borg Scale		9.0		5.0
Transthoracic two-dimensional echocardiography	PAP	60mmHg	PAP	50mmHg
	Right ventricular hypertrophy		Right ventricular hypertrophy	
Physical exercise test				
• Respiratory muscle strength	PiMax	40mmHg	PiMax	53mmHg
	PeMax	25mmHg	PeMax	60mmHg
Six-minute walk test		90m ^a		210m
Geriatric Depression Scale		25/30 severe depression		16/30 mild depression
	Symptoms	77.51	Symptoms	50.18
Quality of life	Physical activities	85.66	Physical activities	62.55
St. George Questionnaire	Impact	70.39	Impact	50.64
	Total score	83.86	Total score	71.54
Long-term oxygen therapy	Flow 2.5L/min for 24 hours		Flow 1.5L/min for 24 hours	

^aThe six-minute walk test, before the retraining program, was stopped due to patient breathlessness. DLCO, diffusion lung capacity for carbon monoxide; FEV₁, Forced expiratory volume in one second; FVC, forced vital capacity; PaO₂, partial arterial pressure of oxygen; PaCO₂, partial pressure of carbon dioxide; PAP, pulmonary artery pressure; PiMax, maximal inspiratory pressure; PeMax, maximal expiratory pressure.

syndrome typically occurs in male smokers and is frequently complicated by pulmonary hypertension, acute lung injury, and lung cancer, which affect disease progression and survival. In the literature there are no reports on the efficacy of physical retraining in patients with CPFE, in contrast with other lung diseases such as chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis where clinical studies have demonstrated the benefits of pulmonary rehabilitation [15]. Clinically relevant improvements and short-term benefits were clearly demonstrated in this report as a result of a retraining program. Although clinical studies on long-term effects within a large patient population are required for definitive conclusions, our observations suggest that integrating pulmonary rehabilitation with pharmacological treatments would be beneficial for patients with CPFE.

Conclusions

In the literature there are no reports on the effects of pulmonary rehabilitation in patients with CPFE. The potential efficacy of aerobic exercise on quality of life and psychological well-being and exercise capacity function in a patient with CPFE has been demonstrated in this case. Our results suggest that exercise should also be considered as a therapeutic option for patients with CPFE, although further studies considering the impact of different types of training in this patient population are required.

Consent

Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

DLCO: diffusion lung capacity for carbon monoxide; FEV 1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; HRCT: high-resolution computed tomography; LTOT: long-term oxygen therapy; PaO₂: partial arterial pressure of oxygen; PaCO₂: partial pressure of carbon dioxide; PAP: pulmonary artery pressure; PiMax: maximal inspiratory pressure; PeMax: maximal expiratory pressure; 6MWT: six-minute walk test, VAS, Visual Analogue Scale.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GDS, GM, AB, and GC analyzed and interpreted the patient data and wrote the article. GDS, GA, and CDG planned and carried out the pulmonary rehabilitation program. All authors read and approved the final manuscript.

Author details

¹Department of Medicine and Health Sciences, "V Tiberio" University of Molise, Campobasso, Italy. ²Institute of Rehabilitation "Villa Margherita Benevento", Unit of Cardiology and Pneumology, Benevento, Italy. ³Department of Cardio-Thoracic and Respiratory Sciences, Second University of Napoli, Napoli, Italy.

Received: 1 September 2014 Accepted: 9 March 2015

Published online: 19 April 2015

References

1. Cottin V, Nunes H, Brillet P. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. *Eur Respir J*. 2005;26:586–93.
2. Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil? *Respir Res*. 2012;13:3.
3. Mazzeo G, Esposito V, Bianco A. Inflammatory effects on human lung epithelial cells after exposure to diesel exhaust micron sub particles (PM1.0) and pollen allergens. *Environ Pollut*. 2012;161:64–9.
4. Esposito V, Lucariello A, Savarese L. Morphology changes in human lung epithelial cells after exposure to diesel exhaust micron sub particles (PM1.0) and pollen allergens. *Environ Pollut*. 2012;171:162–7.
5. Katzenstein AL, Mukhopadhyay S, Zanardi C. Clinically occult interstitial fibrosis in smokers: classification significance of a surprisingly common finding in lobectomy specimens. *Hum Pathol*. 2010;41(3):316–25.
6. De Laurentis G, Paris D, Melck D. Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate. *J Proteome Res*. 2013;12:1502–11.
7. Maldor MJ, Kufel TJ, Pineda LA. Effect of pulmonary rehabilitation on quadriceps fatigability during exercise. *Am J Respir Crit Care Med*. 2001;163:930–5.
8. Decramer M. Response of the respiratory muscles to rehabilitation in COPD. *J Appl Physiol*. 2009;107:971–6.
9. Mereles D, Ehlken N, Kreuzer S. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation*. 2006;114:1482–9.
10. Daniele A, De Rosa A, Nigro E. Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease. *Int J Biochem Cell Biol*. 2012;44:563–9.
11. Nigro E, Scudiero O, Sarnataro D. Adiponectin affects lung epithelial A549 cell viability counteracting TNF α and IL-1 β toxicity through AdipoR1. *Int J Biochem Cell Biol*. 2013;45(6):1145–53.
12. Corbi G, Bianco A, Turchiarelli V. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on sirtuins. *Int J Mol Sci*. 2013;14(6):12696–713.
13. Bianco A, Mazzeo G, Turchiarelli V. Adiponectin: an attractive marker for metabolic disorders in chronic obstructive pulmonary disease (COPD). *Nutrients*. 2013;5:4115–25.
14. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. *Chest*. 2011;139:165–73.
15. Kozu R, Senjyu H, Jenkins SC. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. *Respiration*. 2010;81(3):196–205.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

